OCWP
CCCC icon

Owl Creek Wealth Partners’s C4 Therapeutics CCCC Stock Holding History

Owl Creek Wealth Partners’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.99K Hold
2,140
– – ﹤0.01% 846
2026
Q1 		$5.63K Buy
+2,140
New +$5.04K ﹤0.01% 946

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Owl Creek Wealth Partners's CCCC Position: Q2 2026 in Review

Owl Creek Wealth Partners held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 2,140 shares worth $9.99K. The position accounts for ﹤0.01% of the portfolio, ranked #846.

Owl Creek Wealth Partners first reported a position in CCCC in Q1 2026 and has held it in 2 quarters since. 137 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Owl Creek Wealth Partners held 2,140 shares of C4 Therapeutics worth $9.99K as of Q2 2026.
  • Owl Creek Wealth Partners left its C4 Therapeutics share count unchanged in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #846 holding.
  • Owl Creek Wealth Partners first reported a position in C4 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 137 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.